Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.US-based vaccine developer Agilvax has entered into a collaboration with Swiss-based Humabs BioMed to develop targeted vaccines and immunotherapies to combat diseases with unmet medical needs.
Subscribe to our email newsletter
Under the deal, Agilvax will use Humabs’ antibodies developed from patient survivors of infectious and chronic diseases. The collaboration will contribute to the rapid advancement of Agilvax’s expanding vaccine and immunotherapy pipeline.
Using these antibodies will help promote the development and commercial launch of vaccines and immunotherapies. The company said that these antibodies have been proven to be efficacious both in-vitro and in in-vivo.
Use of these therapeutic antibodies represents the suitable antibody source to identify virus-like-particle (VLP) vaccine candidates and immunotherapies using Agilvax’s new affinity selection technology.
Affinity selection with Humabs’ antibodies will lead to the production of VLPs that induce high-titer, durable and protective antibody responses that mimic the selecting therapeutic monoclonal antibody.
Agilvax president and CEO Federica Pericle said: "Agilvax is committed to developing and increasing accessibility to targeted vaccines and immunotherapies.
"The utilization of Humabs’ antibodies in our product development process greatly increases our ability to fulfill this mission.
"Using antibodies derived from patient survivors ensures the creation of vaccines and immunotherapies that produce strong and precise immune responses, and ultimately improves health outcomes and patient well being."